Interview by Nicola Miller, RARE Revolution,
featuring with Doug Sproule, chief medical officer, ML solutions, a BridgeBio company

“Scientific advances in a single rare disorder help to illuminate the path for therapy development across a spectrum of related conditions. I can’t understate how one victory begets the next and so on. The advances, learning and experiences can benefit other physician scientists, investigators, pharmaceutical and biotech companies who will be able to emulate. This is instrumental in progress.” Doug

---